Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:01 22/05/2024 BST			5-day change	1st Jan Change
4.83 ^USD	-2.42%		+2.55%	-28.94%

04-09	Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	CI
04-03	Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	MT

Synaptogenix, Inc. Announces Resignation of George Perry from the Board of Directors and as Member of All Committees of the Board

October 01, 2021 at 10:09 pm

On September 30, 2021, George Perry resigned from his position as a member of the board of directors of Synaptogenix, Inc. and as a member of all committees of the Board on which he serves. Upon his resignation, Mr. Perry will continue to serve the Company in an advisory capacity as Chairman of the Scientific Advisory Board.

Latest news about Synaptogenix, Inc.

Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	04-08	CI
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	04-03	MT
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	11-01	CI
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	19/07/23	CI
Top Midday Gainers	13/07/23	MT
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell Microcap Index	23/06/23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell Microcap Growth Index	23/06/23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell 3000E Growth Index	23/06/23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell Microcap Value Index	23/06/23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell 3000E Value Index	23/06/23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell 3000E Index	23/06/23	CI
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
North American Morning Briefing : Futures Waver -2-	20/12/22	DJ
Maxim Downgrades Synaptogenix to Hold From Buy	19/12/22	MT
Sector Update: Health Care Stocks Stumble on Friday	16/12/22	MT
Sector Update: Healthcare	16/12/22	MT
Top Midday Decliners	16/12/22	MT
Synaptogenix Shares Decline After Proposed Alzheimer's Disease Treatment Misses Primary Endpoint in Phase 2 Study	16/12/22	MT
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease	16/12/22	CI
Synaptogenix, Inc. announced that it has received $15 million in funding	20/11/22	CI
Synaptogenix Announces $15 Million Private Placement	18/11/22	MT
Synaptogenix, Inc. announced that it expects to receive $15 million in funding	16/11/22	CI

Chart Synaptogenix, Inc.

Duration

Period

More charts

Company Profile

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimerâs disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
SYNAPTOGENIX, INC.	-28.94%	5.24M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.87%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research